So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific research and seems determined to scrap the research grants of Ivy League ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

NHS England has poured investment into hospitals while neglecting other parts of the service, Lord Ara Darzi concluded last year in his report on a “broken system”. The share of the UK health budget ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...